加载中
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
收盘时
US$85.92
+US$1.81 · +2.15%
盘后
US$85.92
US$0.00 · 0.00%
10月12日 17:27 ET
盘中时间采用ET。市场数据可能有所延迟。
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
日内区间
当前US$85.92
52周区间
当前US$85.92
盘中时间采用ET。市场数据可能有所延迟。
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
日内区间
当前US$85.92
52周区间
当前US$85.92
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 46.62亿 USD | 40.33亿 USD | 36.22亿 USD | 29.1亿 USD | 24.49亿 USD |
| 销货成本 | 18.6亿 USD | 15.95亿 USD | 13.33亿 USD | 10.27亿 USD | 7.68亿 USD |
| 毛利 | 28.02亿 USD | 24.38亿 USD | 22.89亿 USD | 18.83亿 USD | 16.81亿 USD |
| 研究与开发 | 5.99亿 USD | 5.52亿 USD | 5.06亿 USD | 4.84亿 USD | 6.04亿 USD |
| 销售、一般及管理费用 | 12.91亿 USD | 12.86亿 USD | 11.85亿 USD | 10.08亿 USD | 8.11亿 USD |
| 营业费用 | 18.9亿 USD | 18.38亿 USD | 16.91亿 USD | 14.92亿 USD | 14.15亿 USD |
| 利息收入 | 1.13亿 USD | 1.34亿 USD | 1.35亿 USD | 2380万 USD | 170万 USD |
| 利息支出 | 1830万 USD | 1900万 USD | 2030万 USD | 1860万 USD | 1880万 USD |
| 折旧和摊销 | 2.52亿 USD | 2.18亿 USD | 1.86亿 USD | 1.56亿 USD | 1.02亿 USD |
| 营业利润 | 9.12亿 USD | 6亿 USD | 5.98亿 USD | 3.91亿 USD | 2.66亿 USD |
| 净利润 | 8.36亿 USD | 5.76亿 USD | 5.42亿 USD | 3.41亿 USD | 2.17亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$95.07
上涨空间 10.65%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2022年6月13日 | 4:1 | — | — |
已生效 2022年6月13日
4:1
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T608.95亿0.05%129.43万亿 JPY0.09%JP¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI11.17亿0.05%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard S&P 500 ETFVOO9.34亿0.05%1.8万亿 USD0.03%US$715.15-0.06%
Vanguard Morningstar Mid-Cap ETFVO7.6亿0.33%2264亿 USD0.03%US$80.92-0.27%
Invesco QQQ Trust, Series 1QQQ6.62亿0.13%5060.67亿 USD0.18%US$745.99-0.70%
Vanguard Morningstar Growth ETFVUG4.47亿0.12%3846亿 USD0.03%US$91.64-0.36%
iShares Core S&P 500 ETFIVV4.22亿0.05%8964.4亿 USD0.03%US$781.44-0.07%
State Street SPDR S&P 500 ETFSPY3.84亿0.05%8172亿 USD0.09%US$778.07-0.06%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Mid-Cap ETFVOInvesco QQQ Trust, Series 1QQQVanguard Morningstar Growth ETFVUGiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
